Diebold Nixdorf EBIT

The latest EBIT for DBD is $140M as of June 2026. That compares with $140M in the prior-year period — up 2.3% year over year. That is below the Technology sector average of $12T. Investors often review this figure alongside Diebold Nixdorf's historical trend and sector peers before judging valuation or financial health.

Over the past year, DBD's EBIT moved from $140M to $140M — a 2.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Diebold Nixdorf's operating scale or balance-sheet position.

Against Technology companies, DBD currently prints $140M for EBIT, while the sector average sits near $12T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Diebold Nixdorf's growth, margins, and balance sheet.

A EBIT figure of $140M for DBD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Technology average is about $12T. Explore the charts below for those layers of context.

After noting DBD's EBIT ($140M), review year-over-year change from $140M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.